À¯·´ À¯¼¼Æ÷ ºÐ¼® ½ÃÀå ±Ô¸ð´Â 2024³â 9¾ï 2,830¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2035³â¿¡´Â 20¾ï 4,570¸¸ ´Þ·¯¿¡ À̸£°í, ¿¹Ãø ±â°£ÀÇ 2025³â-2035³â CAGRÀº 7.53%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
À¯·´¿¡¼´Â À¯¼¼Æ÷ ºÐ¼®¹ýÀÌ ÇöŹ¾×¿¡¼ °³º° ¼¼Æ÷ÀÇ »ó¼¼ÇÑ ´ÙÁß ÆÄ¶ó¸ÞÆ®¸® °Ë»ç¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ±âº»ÀûÀÎ ºÐ¼® ±â¼ú·Î ºÎ»óÇß½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ¹ÙÀÌ¿À ÀǾàǰ °³¹ß, ÀÓ»ó Áø´Ü, ¿¬±¸¿¡ ÇʼöÀûÀÔ´Ï´Ù. Á¾¾çÇÐ, ¸é¿ªÇÐ, °¨¿°Áõ ¿¬±¸´Â ¸é¿ªÆä³ëŸÀÌÇÎ, ¼¼Æ÷ÁÖ±â Æò°¡, ¹ÙÀÌ¿À¸¶Ä¿ È®Àΰú °°Àº ÀÀ¿ë ºÐ¾ß°¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ³ôÀº 󸮷® ½Ã½ºÅÛ°ú ½ºÆåÆ®·³ À¯¼¼Æ÷ ºÐ¼®ÀÇ ÅëÇÕÀÌ ÁøÇàµÇ°í ÀÖ´Â °ÍÀº À¯·´ »ê¾÷¿¡ Å« ±â¼¼¸¦ °¡Á®¿Ô½À´Ï´Ù. ¶ÇÇÑ ¼¼·ÃµÈ ½Ã¾à°ú ºÐ¼® µµ±¸ÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¸ÂÃãÇü ÀÇ·á, ¼¼Æ÷ Ä¡·á, À¯ÀüÀÚ Ä¡·á µîÀÌ Á߽õǴ °Íµµ ¼ö¿ä¸¦ °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù. À̰ÍÀº À¯¼¼Æ÷ ºÐ¼®ÀÌ À¯·´ÀÇ Á¤¹Ð °Ç° ¹× »ý¸í °úÇРȯ°æ¿¡¼ Áß¿äÇÑ ÃËÁøÁ¦ÀÓÀ» ÀÔÁõÇÕ´Ï´Ù.
ÁÖ¿ä ½ÃÀå Åë°è | |
---|---|
¿¹Ãø ±â°£ | 2025-2035³â |
2025³â Æò°¡ | 9¾ï 8,940¸¸ ´Þ·¯ |
2035³â ¿¹Ãø | 20¾ï 4,570¸¸ ´Þ·¯ |
CAGR | 7.53% |
½ÃÀå ¼Ò°³
À¯·´ÀÇ À¯¼¼Æ÷ ºÐ¼® ½ÃÀåÀº ÀÓ»ó Áø´Ü, »ý¸í °úÇÐ ¿¬±¸ ¹× ¹ÙÀÌ¿À ÀǾàǰ °³¹ß ¼ö¿ä Áõ°¡·Î ²ÙÁØÈ÷ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. À¯¼¼Æ÷ ºÐ¼®¹ýÀº ¼¼Æ÷Áֱ⠺м®, ¹ÙÀÌ¿À¸¶Ä¿ È®ÀÎ, ¸é¿ªÆä³ëŸÀÌÇÎ µîÀÇ ÀÀ¿ë ºÐ¾ß¿¡¼ ÀÚÁÖ ÀÌ¿ëµË´Ï´Ù. ¸é¿ªÇÐ, Ç÷¾×ÇÐ, ¾Ï, °¨¿°Áõ ¿¬±¸ µîÀÇ ºÐ¾ß¿¡¼ ±× Á߿伺Àº Áõ°¡ÇÒ »ÓÀÔ´Ï´Ù.
½ºÆåÆ®·³ À¯¼¼Æ÷ ºÐ¼® , ÇÏÀ̽º·çDz ÀåÄ¡, AI¸¦ ±¸»çÇÑ µ¥ÀÌÅÍ ºÐ¼®ÀÇ °³¹ß¿¡ ÀÇÇØ ÃÊ·¡µÈ Á¤¹ÐµµÀÇ Çâ»ó°ú »ç¿ë ¿ëÀ̼ºÀÇ Çâ»óÀÌ ÀÓ»óÀ̳ª ¿¬±¸¿¡¼ÀÇ Æø³ÐÀº ÀÌ¿ëÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. Áø´Ü ÀýÂ÷¿¡¼ À¯¼¼Æ÷ ºÐ¼®ÀÇ »ç¿ëÀº ƯÈ÷ Ç÷¾× ¾Ç¼º Á¾¾ç, ¸é¿ª Áúȯ ¹× ÀÌ½Ä ÀûÇÕ¼º ¸ð´ÏÅ͸µÀ» À§ÇØ À¯·´ ±¹°¡¿¡¼ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹é½Å °³¹ß, ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á, ¸ÂÃãÇü ÀÇ·á¿¡ÀÇ °ü¿©°¡ ³ô¾ÆÁö°í ÀÖ´Â °á°ú, ½ÃÀåµµ È®´ëÇϰí ÀÖ½À´Ï´Ù.
ÀÌ Áö¿ªÀº °·ÂÇÑ °Ç° °ü¸® ÀÎÇÁ¶ó, ±¤¹üÀ§ÇÑ Çмú ¿¬±¸ ³×Æ®¿öÅ©, Çõ½ÅÀûÀÎ Áø´Ü ±â¼úÀÇ Çõ½Å°ú »ç¿ëÀ» Àå·ÁÇÏ´Â À¯¸®ÇÑ ¹ýÀû ƲÀÇ ÇýÅÃÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº Àåºñ °¡°Ý, µ¥ÀÌÅÍ ºÐ¼® ¾î·Á¿ò, Àû°ÝÇÑ ¿î¿µÀÚÀÇ ºÎÁ·Àº ¿©ÀüÈ÷ Å« Àå¾Ö¹°ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Àå¾Ö¿¡µµ ºÒ±¸Çϰí, À¯¼¼Æ÷ ºÐ¼® ½ÃÀåÀº ¿¬±¸°³¹ßºñ Áõ°¡, Àü·«Àû »ê¾÷ Á¦ÈÞ, Á¤¹ÐÁø´Ü¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁü¿¡ µû¶ó À¯·´ Àü¿ª¿¡¼ È®´ë°¡ Áö¼ÓµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Áö¿ªº° ¼¼ºÐÈ
À¯·´
À¯·´ÀÇ À¯¼¼Æ÷ ºÐ¼® ½ÃÀå µ¿Çâ ¹× ÃËÁø¿äÀÎ ¹× °úÁ¦
½ÃÀå µ¿Çâ
ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
ÁÖ¿ä °úÁ¦
Á¦Ç°/À̳뺣ÀÌ¼Ç Àü·« : À¯·´ÀÇ À¯¼¼Æ÷ ºÐ¼® ½ÃÀå ºÐ¼®Àº ÁøÈÇÏ´Â ¿¬±¸ ¹× ÀÓ»ó ¿ä±¸¿¡ ´ëÇÑ ÅëÂû·ÂÀ» Á¦°øÇϸç, °í ÆÄ¶ó¹ÌÅÍ ºÐ¼®, ½ºÆåÆ®·³ ±â´É, ÀÓ»ó Áø´ÜÀ» À§ÇÑ °£¼ÒÈµÈ ¿öÅ©ÇÃ·Î¿ì µî Æ¯Á¤ ¿ä±¸»çÇ×À» ÃæÁ·ÇÏ´Â À¯¼¼Æ÷ ºÐ¼®, ½Ã¾à ¹× ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀ» »ç¿ëÀÚ Á¤ÀÇ °³¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼ºÀå/¸¶ÄÉÆÃ Àü·« : ÀÌ º¸°í¼´Â Çмú ¿¬±¸, ¸é¿ªÁ¾¾çÇÐ, °¨¿°Áõ Áø´Ü°ú °°Àº ÁÖ¿ä ºÎ¹® ¹× ƯÁ¤ Áö¿ª ±âȸ¿¡ ¸Â´Â Ÿ°Ù ¸¶ÄÉÆÃ Àü·«À» ±¸ÇöÇÏ¿© °í°´ Âü¿©µµ¸¦ ³ôÀÌ°í º¸±ÞÀ» °¡¼ÓÈÇÏ´Â Á¶Á÷À» Áö¿øÇÕ´Ï´Ù.
°æÀï Àü·« : ±â¾÷Àº Àåºñ È®À强, »ç¿ë ÆíÀǼº, ½Ã¾à ȣȯ¼º, ÆÇ¸Å ÈÄ Áö¿ø, ¼¼Æ÷ Ä¡·á ¹× ¸é¿ªÆä³ëŸÀÌÇΰú °°Àº Ư¼ö ¿ëµµ¸¦ Æ÷ÇÔÇÏ¿© Ÿ°Ù Áö¿ªÀÇ ÃÖÁ¾ »ç¿ëÀڷκÎÅÍ Æ¯º°È÷ Æò°¡µÇ´Â Ư¡À» °Á¶ÇÔÀ¸·Î½á À¯¼¼Æ÷ ºÐ¼® Á¦Ç°À» Â÷º°ÈÇÒ ¼ö ÀÖ½À´Ï´Ù.
This report can be delivered in 2 working days.
Introduction to Europe Flow Cytometry Market
The Europe flow cytometry market is projected to reach $2,045.7 million by 2035 from $928.3 million in 2024, growing at a CAGR of 7.53% during the forecast period 2025-2035. In Europe, flow cytometry has emerged as a fundamental analytical technique that allows for in-depth multiparametric examination of individual cells in suspension. It is essential to the region's biopharmaceutical development, clinical diagnostics, and research. In oncology, immunology, and infectious disease research, applications like immunophenotyping, cell cycle evaluation, and biomarker identification are extensively used. The increasing integration of high-throughput systems with spectral flow cytometry is driving significant momentum in the European industry. Demand is also being accelerated by the growing usage of sophisticated reagents and analytical tools, as well as by the growing emphasis on personalized medicine, cell and gene therapy, and more. This establishes flow cytometry as a crucial facilitator in the precision healthcare and life sciences environment in Europe.
KEY MARKET STATISTICS | |
---|---|
Forecast Period | 2025 - 2035 |
2025 Evaluation | $989.4 Million |
2035 Forecast | $2,045.7 Million |
CAGR | 7.53% |
Market Introduction
The flow cytometry market in Europe is growing steadily, owing to rising demand in clinical diagnostics, life sciences research, and biopharmaceutical development. Flow cytometry is frequently utilized in applications including cell cycle analysis, biomarker identification, and immunophenotyping because it allows for quick, multiparametric study of individual cells. In disciplines including immunology, hematology, cancer, and infectious disease research, its importance is only increasing.
Wider usage in clinical and research contexts is being supported by improvements in precision and usability brought about by developments in spectral flow cytometry, high-throughput equipment, and AI-powered data analysis. The use of flow cytometry in diagnostic procedures is growing in European nations, particularly for the surveillance of hematologic malignancies, immunological diseases, and transplant compatibility. The market is also growing as a result of its growing involvement in vaccine development, cell and gene therapies, and customized medicine.
The region benefits from a strong healthcare infrastructure, extensive academic research networks, and favorable legislative frameworks that encourage innovation and use of innovative diagnostic technology. High equipment prices, the difficulty of interpreting data, and a lack of qualified operators are still significant obstacles, though. Notwithstanding these obstacles, the market for flow cytometry is anticipated to continue expanding throughout Europe due to rising R&D expenditures, strategic industry partnerships, and the rising need for precision diagnostics.
Regional Segmentation
Europe
Europe Flow Cytometry Market Trends, Drivers and Challenges
Market Trends
Key Market Drivers
Major Challenges
How can this report add value to an organization?
Product/Innovation Strategy: The Europe flow cytometry market analysis provides insights into evolving research and clinical needs, enabling organizations to develop customized flow cytometry instruments, reagents, and software solutions that address specific requirements such as high-parameter analysis, spectral capabilities, or streamlined workflows for clinical diagnostics.
Growth/Marketing Strategy: The report helps organizations implement targeted marketing strategies tailored to key segments such as academic research, immuno-oncology, or infectious disease diagnostics and specific regional opportunities, improving customer engagement and accelerating adoption.
Competitive Strategy: Organizations can differentiate their flow cytometry offerings by emphasizing features particularly valued by end-users in target regions, such as instrument scalability, ease of use, reagent compatibility, after-sales support, or specialized applications like cell therapy or immunophenotyping.
Scope and Definition